Rubicon Organics Q2 revenue rises on yield gains at Pacifica facility
Reuters2026/08/12 11:17
Overview
Canada premium cannabis producer's Q2 net revenue grew 23% yr/yr, driven by facility yield gains
Adjusted EBITDA for Q2 fell 18% yr/yr, reflecting investments to scale production
Company maintained #1 premium licensed producer position in Canada with increased market share
Outlook
Company expects net revenue and Adjusted EBITDA to ramp up in H2 2026
Rubicon expects Cascadia facility yields to reach target by end of 2026
Company anticipates margin benefits from 2026 projects to be fully realized by early 2027
Result Drivers
FACILITY YIELD GAINS - Co said revenue growth was driven by improved yields and efficiency at the Pacifica facility
CASCADIA RAMP-UP - Initial revenues from the Cascadia facility contributed to Q2 results as production came online
INVESTMENTS IMPACT EBITDA - Adjusted EBITDA declined due to investments to scale the business and ramp up Cascadia
Company press release: ID:nGNX3BmVVd
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Revenue |
Beat |
C$18.50 mln |
C$16.60 mln (2 Analysts) |
Q2 Adjusted EBITDA |
|
C$1.10 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Rubicon Organics Inc is C$1.15, about 130% above its August 11 closing price of C$0.50
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 7 three months ago
Reuters Recommended Reads
Aug 10 - Canadian cannabis producer Village Farms beats 'Q2 sales, EPS estimates on record yields, exports
Aug 11 - Canada's Organigram Q3 revenue beats on Sanity acquisition; CFO to exit
Aug 11 - Vireo Growth Q2 revenue jumps on acquisitions
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Thailand: Middle East shock tests growth – DBS
Webuild files takeover offer document for Trevi with Italy’s Consob
Blockchain Association backs SEC's proposal to scrap outdated NMS rules, citing tokenization benefits
Pila Pharma wins EMA approval for 12-week obesity trial of XEN-D0501